首页 › 基金 › GREAT POINT PARTNERS LLC › EPRX
GREAT POINT PARTNERS LLC 对 EPRX 的持仓历史
EUPRAXIA PHARMACEUTICALS INC · 医疗保健
GREAT POINT PARTNERS LLC 在 Q2 2026 的 13F 申报中披露持有 EPRX(EUPRAXIA PHARMACEUTICALS INC)1,200,000 股,市值约 US$7.9M,约占其申报组合的 1.67%,在其申报持仓中市值排名第 22 位。 GREAT POINT PARTNERS LLC 最近 4 个申报季度中有 4 个季度披露了 EPRX 持仓,最早可追溯至 Q3 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
GREAT POINT PARTNERS LLC 对 EPRX 的持仓演变
GREAT POINT PARTNERS LLC 于 Q3 2025 首次披露 EPRX 持仓:1,200,000 股(约 US$7.1M)。 该持仓在 Q4 2025 达到峰值 1,200,000 股,市值约 US$9.1M。 在 4 次申报中,GREAT POINT PARTNERS LLC 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 1,200,000 股、市值约 US$7.9M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2025 | 1.20M | $7.08M | 新进 |
| Q4 2025 | 1.20M | $9.06M | 持有 |
| Q1 2026 | 1.20M | $8.69M | 持有 |
| Q2 2026 | 1.20M | $7.93M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 EPRX 与 13F 数据
EPRX(EUPRAXIA PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 69 只申报持有 EPRX,申报仓位最大的包括:Vivo Capital, LLC (US$8.9M), PFM Health Sciences, LP (US$8.0M), Ikarian Capital, LLC (US$5.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 EPRX 的基金
- Vivo Capital, LLC 1.35M 股 · $8.92M · Q2 2026
- PFM Health Sciences, LP 1.21M 股 · $8.00M · Q2 2026
- Ikarian Capital, LLC 809.74K 股 · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K 股 · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K 股 · $4.04M · Q2 2026
- Velan Capital Investment Management LP 352.00K 股 · $2.33M · Q2 2026
- Aisling Capital Management LP 325.00K 股 · $2.15M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K 股 · $1.67M · Q2 2026
- Delaney Capital Management Ltd. 117.20K 股 · $767.86K · Q2 2026
- Lynx1 Capital Management LP 10.00K 股 · $66.10K · Q2 2026
更多关于 GREAT POINT PARTNERS LLC
常见问题
How long has GREAT POINT PARTNERS LLC held EPRX?
GREAT POINT PARTNERS LLC has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is GREAT POINT PARTNERS LLC's current position in EPRX?
As of Q2 2026, GREAT POINT PARTNERS LLC holds 1.20M shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $7.93M, representing 1.67% of its reported portfolio and ranking #22.
Has GREAT POINT PARTNERS LLC been buying or selling EPRX?
In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC held unchanged its position in EPRX. The position peaked in Q4 2025 at 1.20M shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, Ikarian Capital, LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.